CRISPR Therapeutics AG Target Price

See CRISPR Therapeutics AG's analyst price targets ($69) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$52.96

Average Target Price

$68.75

29.8% upside

4 analysts in the last 4 months

High: $80 | Low: $55

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-06	Goldman Sachs	$55	3.9% upside
2026-07-08	H.C. WainwrightMitchell Kapoor	$80	51.1% upside
2026-06-12	UBS	$80	51.1% upside
2026-06-11	Morgan StanleyMaxwell Skor	$60	13.3% upside
2026-05-13	Bernstein	$56	5.7% upside
2026-05-11	Evercore ISI	$76	43.5% upside
2026-02-17	Morgan Stanley	$33	37.7% downside
2026-02-14	Chardan CapitalGeulah Livshits	$76	43.5% upside
2026-02-13	Needham	$82	54.8% upside
2026-02-13	Evercore ISI	$74	39.7% upside
2025-11-26	Chardan Capital	$74	39.7% upside
2025-11-11	RBC CapitalLuca Issi	$50	5.6% downside
2025-10-13	Wells FargoYanan Zhu	$75	41.6% upside
2025-02-03	H.C. WainwrightMitchell Kapoor	$65	22.7% upside
2024-11-06	OppenheimerJay Olson	$95	79.4% upside
2024-11-05	Leerink PartnersRick Bienkowski	$67	26.5% upside
2024-08-12	Truist FinancialJoon Lee	$100	88.8% upside
2024-08-06	NeedhamGil Blum	$84	58.6% upside
2024-08-06	Stifel NicolausBenjamin Burnett	$59	11.4% upside
2024-08-06	RBC CapitalLuca Issi	$60	13.3% upside
2024-05-09	Robert W. BairdJack Allen	$52	1.8% downside
2022-11-23	Citigroup	$63	19% upside
2022-08-09	Chardan CapitalGeulah Livshits	$79.3	49.7% upside
2022-06-17	BMO CapitalKostas Biliouris	$98	85% upside
2022-04-28	Credit Suisse	$78	47.3% upside
2022-02-16	NeedhamGil Blum	$170	221% upside
2022-02-15	Leerink PartnersRick Bienkowski	$120	126.6% upside
2022-01-07	Wells FargoYanan Zhu	$105	98.3% upside
2021-11-04	OppenheimerJay Olson	$172	224.8% upside
2021-10-12	Piper SandlerEdward Tenthoff	$180	239.9% upside
2021-08-16	Canaccord GenuityArlinda Lee	$160	202.1% upside
2021-06-11	Roth CapitalAnthony Butler	$171	222.9% upside
2021-04-21	JefferiesMaury Raycroft	$172	224.8% upside

CRISPR Therapeutics AG (CRSP) FAQ

As of the most recent data, CRSP shows a target price of $69. Scroll down for historical charts and peer comparison views.

If CRISPR Therapeutics AG moved to the average analyst target of $69, shares would be roughly 29.8% higher than $52.96. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of CRISPR Therapeutics AG's earnings trajectory.

Besides this target price page, Stockcircle has CRISPR Therapeutics AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $69) with ownership activity and broader fundamentals.

CRISPR Therapeutics AG's target price is $69; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.